TPG: a Phase 2 Trial of Polatuzumab Vedotin, Glofitamab, and Tafasitamab as Chemotherapy-sparing First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Brown University
Summary
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Ability to understand and the willingness to sign a written informed consent document and to comply with the study protocol procedures. 2. Age ≥18 years. 3. Histologically confirmed diagnosis of DLBCL, or HGBL, according to 5th edition WHO classification. Eligible WHO entities include: * Diffuse large B-cell lymphoma, not otherwise specified (NOS) * T-cell/histiocyte-rich large B-cell lymphoma * DLBCL/HGBL with MYC and BCL2 rearrangements * Large B-cell lymphoma with IRF4 rearrangement * HGBL with 11q aberration * EBV-positive diffuse large B-cell lym…
Interventions
- DrugTafasitamab
Cytolytic monoclonal antibody targeting CD19.
- DrugPolatuzumab vedotin
CD79b-targeting antibody-drug conjugate
- DrugGlofitamab
CD20xCD3 bispecific antibody
- DrugObinutuzumab
Anti-CD20 monoclonal antibody
Location
- Rhode Island HospitalProvidence, Rhode Island